Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
